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Abstract
Cervical cancer is frequently associated with HPV infection. The expression of E6 and E7 HPV oncoproteins is a key factor in
its carcinogenicity and might also influence its virulence, including metastatic conversion. The cellular mechanisms involved
in metastatic spread remain elusive, but pro-adhesive receptors and their ligands, such as SDF-1a and CXCR4 are implicated.
In the present study, we assessed the possible relationship between SDF-1a/CXCR4 signaling, E6/E7 status and the
metastatic process. We found that SDF-1a stimulated the invasion of E6/E7-positive cancer cell lines (HeLa and TC-1) in
Matrigel though CXCR4 and subsequent Rho/ROCK activation. In pulmonary metastatic foci generated by TC-1 cells IV
injection a high proportion of cells expressed membrane-associated CXCR4. In both cases models (in vitro and in vivo) cell
adhesion and invasion was abrogated by CXCR4 immunological blockade supporting a contribution of SDF-1a/CXCR4 to
the metastatic process. E6 and E7 silencing using stable knock-down and the approved anti-viral agent, Cidofovir decreased
CXCR4 gene expression as well as both, constitutive and SDF-1a-induced cell invasion. In addition, Cidofovir inhibited lung
metastasis (both adhesion and invasion) supporting contribution of E6 and E7 oncoproteins to the metastatic process.
Finally, potential signals activated downstream SDF-1a/CXCR4 and involved in lung homing of E6/E7-expressing tumor cells
were investigated. The contribution of the Rho/ROCK pathway was suggested by the inhibitory effect triggered by Cidofovir
and further confirmed using Y-27632 (a small molecule ROCK inhibitor). These data suggest a novel and highly translatable
therapeutic approach to cervix cancer, by inhibition of adhesion and invasion of circulating HPV-positive tumor cells, using
Cidofovir and/or ROCK inhibition.
Citation: Amine A, Rivera S, Opolon P, Dekkal M, Biard DSF, et al. (2009) Novel Anti-Metastatic Action of Cidofovir Mediated by Inhibition of E6/E7, CXCR4 and
Rho/ROCK Signaling in HPV
+ Tumor Cells. PLoS ONE 4(3): e5018. doi:10.1371/journal.pone.0005018
Editor: Neil Hotchin, University of Birmingham, United Kingdom
Received October 19, 2008; Accepted February 16, 2009; Published March 26, 2009
Copyright:  2009 Amine et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: A. A. and S. R. are fellows of the Association pour la Recherche sur le Cancer. D. B. acknowledges a grant from Electricite de France. This study was
partly supported by the Association pour la Recherche sur le Cancer, contract nu 3881 and 4970. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: vozenin@igr.fr
Introduction
Tumor cell metastasis remains the main cause of death in cancer
patients. The mechanisms involved in the formation of secondary
tumors at distant sites are complex. Several molecular determinants
are required to proceed through the ‘‘active’’ steps of the metastatic
process, such as escape from anoikis/apoptosis, preferential homing
to specific organs, extravasation and growth in such secondary sites.
Numerous target molecules have been implicated in organ-specific
tumor metastasis but its detailed mechanism remains obscure.
Current therapeutic optionsformetastaticcancerarelargely limited
to classical cytotoxic agents in addition to endocrine manipulation
for hormone-sensitive cancers [1].
Specific extracellular chemokines play critical roles in deter-
mining organ-selective metastasis, altering chemo-attraction,
adhesion and tumor cell survival. Among them, stromal-derived
factor-1 (SDF-1a or CXCL12) and its receptor, CXCR4, have
been increasingly studied [2]. SDF-1a is a small secreted peptide
belonging to the CXC family that regulates migration of
leukocytes, especially during immune and inflammatory reactions
[3,4]. The SDF-1a receptor (CXCR4/CD186) is a G-protein
coupled receptor with various physiological functions such as
leukocyte trafficking, B-cell lymphopoiesis, myelopoiesis, and
gastrointestinal vascularisation [5,6]. The interaction between
SDF-1a and CXCR4 can elicit a direct chemo-attractive action on
breast cancer cells [7,8] and CXCR4 expression currently used in
conjunction with CD133 to define metastatic stem cells [9]
suggesting that its pro-metastatic action could broadly apply to
metastatic cancer including cervical carcinoma. SDF-1a protein is
indeed highly synthesized at common metastatic sites, including
bone marrow, liver and lung [10] and CXCR4 is highly expressed
on cervix cancer cells [11]. It has been suggested that ligand-
receptor interaction and subsequent activation of the SDF-1a/
CXCR4 complex may preferentially arrest cancer cells in the
vascular beds of SDF-1a2expressing organs and could contribute
to metastatic homing and invasion of these cells in such specific
organs [2]. The functional consequences of SDF-1a/CXCR4 axis
activation include modulation of cell motility, adhesion and
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e5018invasion dependent on actin cytoskeleton dynamics [12,13]. Such
phenotypic alterations are triggered, at least in part, by the small
GTPases RhoA, rac1 and cdc42 [14] and activation of their
downstream effectors, Rho kinases/ROCK/ROK, leading to
myosin phosphorylation [15,16,17,18,19].
One causative agent in cervix carcinogenesis is infection with
high risk human papilloma viral subtypes, including HPV-16 and -
18 [20]. Expression of the oncoprotein, E6 and E7, have an
established role in the initiation and growth of cervix cancer
mediated by the inhibition of the products of the tumor suppressor
genes p53 and pRB [21]. Human HPV genotype has some
prognostic value in early-stage cervical cancers [22]; conversely
positive HPV status correlates with reduced tumour aggressiveness
and improved patient outcome, especially in Head & Neck tumors
[23]. Although a causal aetiology for oncogenic HPV in metastatic
spread remains an open question, several lines of evidence support
its possible role in this process. For example, isogenotypic HPV
DNA has been found in primary tumours and metastatic lymph
nodes in the same patients [24,25]; stable transfection of HPV-16
E6 and E7 genes increased the pro-metastatic conversion in two
non-isogenic mouse cell lines (NCTC2555 and NIH3T3) [26]; and
HPV-16 E6/E7 enhanced migration of normal human keratino-
cytes [27] and promoted cell invasion and metastasis of human
breast cancer cells [28].
Blood-born metastasis of cervical cancer are not uncommon
especially in third world countries, prompting us to investigate the
relationship between the SDF-1a/CXCR4 axis, the HPV-16/18-
E6/E7 genes, and tumor metastasis. We show that SDF-1a
stimulates HPV-positive cell lines (HeLa and TC-1) invasiveness
both in vitro and in vivo and this was mediated though CXCR4 and
subsequent Rho/ROCK activation. We then show that inhibition
of E6 and E7 by knock-down approach and a pharmacological
anti-viral agent, Cidofovir (HPMPC, VISTIDH) [29] strongly
abrogated SDF-1a-induced invasion, decreased CXCR4 expres-
sion in vitro and inhibited formation of lung metastasis. Based on
these data, we propose a new pharmacological approach to inhibit
metastasis in cervical cancer patients through the inhibition of E6/
E7 with Cidofovir and ROCK.
Results
CXCR4 immunological blockade inhibits cell invasion in
vitro
To determine a potential role for the SDF-1/CXCR4 axis in
cells’ invasiveness, SDF-1a was used as chemoattractant on the
two HPV-positive cell lines HeLa and TC-1 and one HPV-
negative cell line B16F10. SDF-1a at 100 ng/ml significantly
enhanced invasion in the three cell types tested (Figure 1A, B, C)
(*** P,0.01). CXCR4 was then blocked using a specific
monoclonal blocking antibody. This blocking antibody markedly
suppressed cell invasion in all three cell types (10 mg/mL; #
P,0.01).
E6 and E7 inhibition by Cidofovir treatment and KD
blocks cell invasion in vitro
We next examined whether the presence of HPV oncoproteins
could contribute to the invasiveness of HeLa and TC-1 cells using
the E6/E7 inhibitor, Cidofovir (CDF). Western-blot confirmed E6
down-regulation in HeLa and TC-1 cells treated by Cidofovir
(Figure 1A, B WB panels). Six days of incubation with Cidofovir
inhibited E6 more potently than 3 days and these conditions were
therefore used in subsequent experiments (Figure 1A, B). In HeLa
cells E6 inhibition was associated with P53 restoration (Figure 1A).
To exclude potential non-specific drug cytotoxicity, we next
determined the effect of Cidofovir on cell survival and apoptosis.
Cidofovir treatment reduced HeLa cell survival by 10% (ns) and
TC-1 survival by 20% (ns), as measured by dimethylthiazol
diphenyl tetrazolinuim (MTT) assay (Figure S1A). Consistently,
Cidofovir treatment increased apoptosis in HeLa cells by 8% and
in TC-1 by 20% (p,0.05) (Figure S1B). These measurements were
used to adjust the number of seeded cells, to ensure a reliable
comparison between groups. In each group, an expected 5610
5
living cells were seeded into the top chamber of a Matrigel
transwell. HPV-negative cells B16F10 were used as controls.
Cidofovir significantly abrogated the SDF-1a-induced invasiveness
of HPV-postive cells i.e. HeLa and TC-1 (Figure 1A, B; #P,0.01)
but had no inhibitory effect on HPV-negative cells i.e. B16F10
(Figure 1C), thereby suggesting that the capacity of Cidofovir to
modulate invasiveness is dependant on HPV status. To further
investigate possible role of E6 and E7 oncoproteins in the
metastatic process the two oncoproteins were knocked-down
(KD) in HeLa cells using a method recently described by Biard
[30]. This stable KD approach was used because of the multiple
copy of E6/E7 insertion in the genome of HeLa cells making
traditional knock-out experiments non-viable. Three independent
clones (100, 102, 103) were produced and showed approximately
80% inhibition of the targeted genes as shown in Q-RT-PCR and
Western-blot (Figure 2A). This inhibition rate is stable in time (15
passages tested so far). Targeting E6 resulted in E6 and E7 switch-
off and vice et versa as already described [31,32] and due to their
common ORF. CXCR4 gene expression was reduced by 90% in
the clone 102 (p,0.01), by 50% in the clone 103 (p,0.05) while a
trend toward reduction was obtained in the clone 100 (Figure 2B).
Cell invasion was then monitored using matrigel assays in presence
of SDF-1a or not and with clones pre-treated or not with
Cidofovir (CDF) (Figure 2C). In the three E6/E7 KD clones (100,
102, 103) constitutive migratory activity was reduced (p,0.05). In
addition, SDF-1a pro-migratoy action was impaired in the three
KD clones. In the clones 102 and 103, SDF-1a was unable to
stimulate cell migration (Figure 2C) consistently the reduced
CXCR4 gene expression measured by Q-RT-PCR (Figure 2B). In
the clone 100, SDF-1a stimulated cell migration consistently with
the persistent CXCR4 gene expression found in this clone
(Figure 2B). Cidofovir treatment was then performed on the three
KD clones. In the clone 102 and 103, Cidofovir had no additional
effect as cell migration was already abrogated in these clones.
However, Cidofovir reduced cell migration in the clone 100 as
compared to control clone. Collectively, these results support a
direct involvement of E6 and E7 proteins in the invasiveness of
HeLa cells in our experimental conditions.
CXCR4 inhibition blocks experimental metastasis in vivo
To extend the biological relevance of these in vitro findings, an
experimental model of lung metastasis was used [33]. In this
model, mouse TC-1 cells, generated by transduction of C57BL/6
(B6) primary lung epithelial cells with a retroviral vector expressing
HPV16 E6/E7 [33], are intravenously injected into C57BL/6
mice, resulting in a respiratory distress syndrome 15 days after
injection. The morbidity of the animals was caused by dramatic,
progressive metastatic lesions invading the lung parenchyma
(‘Untreated Control’, Figure 3A and B). Such metastatic foci
mainly comprised .90% CXCR4
+ tumor cells (‘Untreated
Control’, Figure 3C). The use of a monoclonal antibody blocking
CXCR4 surface receptors prior to intravenous injection of TC-1
cells did not affect cell viability (98% living cells after incubation
with the blocking antibody for 30 min.), but remarkably, almost
completely abrogated tumor cell homing and invasion to the lung
(‘Ab anti-CXCR4’; Figure 3A). In the antibody-pretreated group,
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PLoS ONE | www.plosone.org 2 March 2009 | Volume 4 | Issue 3 | e5018Figure 1. In vitro cell invasion is stimulated by the SDF-1/CXCR4 pathway independently from HPV status. The modulation of E6
expression was monitored using Western-blot in HPV-positive HeLa (A) and TC-1 (B) cells and in HPV-negative B16F10 (C) cells, after 3 and 6 days of
incubation with Cidofovir (CDF). Modulation of P53 expression was assessed in HeLa cells after CDF incubation (A). Cell invasion was measured using
a Matrigel assay in HeLa (A), TC-1 (B) and B16F10 (C) cells. Recombinant human CXCL12/SDF-1 (100 ng/mL; R&D Systems) was used as
chemoattractant and modulation of cell migration was recorded after treatment with CXCR4-blocking antibody or/and Cidofovir (CDF). The invasion
rate was determined by counting crystal violet-stained cells. Invasion was stimulated by SDF-1a/CXCR4 independently from the HPV status of the
cells but Cidofovir anti-invasive action was restricted to the two HPV-positive cell lines. Three independent experiments with three chambers each
time were performed. ***P,0.01, for a statistically true difference, as compared to the untreated group. # P,0.01 compared to SDF-1a-treated
group.
doi:10.1371/journal.pone.0005018.g001
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PLoS ONE | www.plosone.org 3 March 2009 | Volume 4 | Issue 3 | e5018Figure 2. Silencing of E6 and E7 showed contribution of the oncoproteins to the pro-migratory phenotype of HeLa cells. (A)
Quantitative RT-PCR analysis of E6 and E7 mRNA level and E6 protein expression in knock-down HeLa cells lines. E6 and E7 expression were
respectively knocked-down using the pEBVsiRNA in 100, and 102, 103. Inhibition was statically significant P,0.04. (B) Quantitative RT-PCR analysis of
CXCR4 mRNA level in clones
KD with CXCR4- specific probe. ***P,0.01 and **P,0.05. (C) Cell invasion was measured using a Matrigel assay in E6
KD
(100) and E7
KD (102, 103) and compared to migration of a control HeLa clone (scrambled sequence). All Experiments were conducted in presence of
Hygromycin (125 mg/mL) with DMEM+10% FCS; DMEM+SDF-1a (100 ng/mL); CDF and DMEM+SDF-1a (100 ng/mL). Three independent experiments
with three chambers each time were performed. **P,0.05, for a statistically true difference, as compared to the control clone with DMEM+FCS. #
P,0.05 and ## P,0.01 compared to the control clone with DMEM+SDF-1a. u P,0.05 and uu P,0.01 compared to the control clone with CDF and
DMEM+SDF-1a.
doi:10.1371/journal.pone.0005018.g002
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PLoS ONE | www.plosone.org 4 March 2009 | Volume 4 | Issue 3 | e5018Figure 3. TC-1 cell lung metastasis is mediated by the CXCR4 in vivo. TC-1 cells (1610
6) were injected into mice tail veins either without or
with pre-treatment with CXCR4-blocking antibody (2B11), irrelevant antibody (CD71), or trypsin/EDTA. (A). Representative Hematoxylin-Eosin-
Saffranin (HES)-satined sections of lungs of mice are shown. Digitization of the whole slides was performed for each animal/treatment type.
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injection versus a dramatic tumor invasion in the control and non
relevant antibody-treated groups (‘Ab anti-CD71’; Figure 3A).
Quantification of these data was by calculation of the mean
metastatic surface area measured in the cohort of animals used for
each condition (Figure 3B, ‘Ab anti-CXCR4’, *** P,0.01). The
remaining foci comprised CXCR4-positive tumor cells, suggesting
that blockade was not total (Figure 3C, ‘Ab anti-CXCR4’). The
specificity of these findings was then confirmed in three
independent sets of control experiments. First, receptors were
depleted from the surface of the cells by a 5 min trypsin/EDTA
pre-incubation at 37uC. While this pre-treatment did not affect
mass culture cell survival (data not shown), it almost fully
abrogated tumor focus formation (n=7/7 mice; ‘trypsin/EDTA
panel’, Figure 3A, B, *** P,0.01). Second, pre-incubation of TC-
1 cells with an irrelevant antibody (CD71) had no effect on the
formation of TC-1 metastatic lesions, comparable to that in
controls (n=5/5 mice; Figure 3A and B; ‘Ab anti-CD71’). Third,
histologic examination of the spleen showed normal morphology,
indicating an absence of immune-related scavenging of the TC-1
cells/blocking antibody complex (n=16/16 mice; Figure S2),
suggesting that TC-1 cells were not eliminated by the immune
system. Collectively, these experiments strongly suggested that
pulmonary adhesion and invasion leading to subsequent prolifer-
ation of TC-1 foci into the lung is directly mediated by the
CXCR4 pathway in vivo.
Cidofovir decreases CXCR4 expression
Because Cidofovir treatment inhibits cell invasion in vitro,w e
reasoned that Cidofovir might alter the abundance of CXCR4
mRNA and cell surface protein level. Q-RT-PCR analysis
confirmed this assumption, showing a two-fold decrease in
CXCR4 mRNA levels after TC-1 cellular incubation with
Cidofovir (Figure 4A, ** P,0.05), whereas in the negative control,
SDF-1a did not alter CXCR4 mRNA levels. FACS analysis
confirmed that Cidofovir reduced CXCR4 receptors on the
surface of both HeLa and TC-1 cells (Figure 4B: P,0.05 and
Figure 4C: P,0.01). Immunofluorescence analysis confirmed the
aforementioned data, showing both the expected exclusive
membrane location of CXCR4 and its’ reduced abundance on
the cell surface after Cidofovir treatment (Figure 4D)
Cidofovir inhibits experimental metastasis in vivo
We then examined whether pre-treatment of TC-1 cells with
Cidofovir could also abrogate metastasis in vivo. Before to this, we
excluded any non-specific anti-clonogenic effect of Cidofovir in
vitro by clonogenic survival assay and in vivo by subcutaneous
engraftment of TC-1 and subsequent monitoring of tumor growth
(Figure S3). In vitro, the highest concentration of Cidofovir (10 mg/
mL) reduced TC-1 clonogenic capacity by 22% (Figure S3A) and
was used to pre-treat TC-1 cells before their subcutaneous
injection. In mice injected with 4 million of untreated TC-1 cells,
tumor engraftment defined by a 5 mm3 lesion took 10 days
(Figure S3B) whereas delayed engraftment (23 days) was observed
in mice injected with Cidofovir-treated TC-1 cells (Figure S3B).
However the slopes of the tumor growth curves were similar in the
untreated and Cidofovir-treated groups, suggesting that Cidofovir
delayed TC-1 cells engraftment to the lung but has no effect on the
clonogenic capacity of TC-1 per se.
We subsequently performed metastasis experiments. In the first
set of experiments, mice were injected with TC-1 cells pretreated
or not with Cidofovir (10 mg/mL). Notably, Cidofovir pre-
treatment markedly abrogated both lung adhesion and invasion
of TC-1 cells, completely in 4/6 mice, and in the two remaining
mice, only two small microscopic metastatic foci were present 15
days after injection (both comprising 1–2 CXCR4+ tumor cells
(Figure 5A, 5B middle panel, 5C, *** P,0.01). In a second set of
experiments, Cidofovir (100 mg/kg) was systemically delivered to
mice 2 h before IV injection of untreated TC-1 cells and mice
were injected with Cidofovir for the 8 subsequent days.
Interestingly, systemic Cidofovir treatment also decreased the
number and size of TC-1 cell-induced metastatic foci: two mice
out of eight exhibited lungs completely free of metastasis and in the
remaining animals, metastatic foci were small with intra-vascular
and intra-parenchymal locations. Quantification of such metastat-
ic versus normal lung areas clearly showed the anti-metastatic
efficacy of Cidofovir (Figure 5B, *** P,0.01).
The Rho/ROCK pathway is activated by SDF1a and is
inhibited by Cidofovir
Because Rho/ROCK activation is involved in CXCR4
signaling, we examined its’ possible activation by the SDF-1a
ligand. In E6/E7 positive cell lines HeLa and TC-1, pre-
incubation with SDF-1a resulted in clear activation of the Rho
protein, as quantified by pull-down assay (Figure 6A, ** P,0.01).
In contrast, cells exposed to Cidofovir demonstrated a significant
decrease in both baseline and SDF-1a-activated levels of the Rho-
GTP active form (Figure 6A, *** P,0.01). Although not
quantitative, immunofluorescence assays confirmed pull-down
result: SDF-1a-treated HeLa cells exhibited a membrane-associ-
ated Rho location, consistent with Rho’s activation status;
Cidofovir treatement decreased the fluorescence brightness
(Figure 6B). We also indirectly examined ROCK activation by
assaying the phosphorylation status of the myosin light chain
(MLC), confirming that Cidofovir inhibited ROCK activity in
both cell types (Figure 6C) *** P,0.01).
ROCK inhibition partially blocks TC-1 metastasis
This last result suggested that the Rho/ROCK pathway may be
involved in tumor cell invasiveness. We addressed this hypothesis
in vitro and in vivo using a well established pharmacological
inhibitor of ROCK, the small molecule Y-27632. Blockade of
ROCK reduced both tumor cell invasion in vitro (Figure 7A) as well
as pulmonary homing and colonisation in vivo (Figure 7B, C),
supporting our former data. However, cellular Y-27632 exposure
was less efficient at reducing matrigel invasion and metastasis than
either CXCR4 blocking antibody or Cidofovir, suggesting that
additional intracellular signaling is probably activated downstream
of CXCR4 in E6/E7 expressing cells.
Discussion
Clinical reports on patients with HPV positive tumors with
distant metastasis in organs such as lung, liver and bone suggested
an association between the presence of oncogenic human
papillomaviral subtypes and the metastatic process [24,25,26].
More recent transfection/infection studies demonstrated that the
oncoprotein E7 was a causative agent in early metastatic
Histopathological analysis was done after delineation of metastases (dashed line) vs whole lung area (B) on each HES-stained section with the ImageJ
software. The lung metastasis indices within each cohort of mice are expressed as fold decrease (+/2SEM) over untreated controls ***P,0.01. (C)
Representative sections of CXCR4 immunostaining are shown.
doi:10.1371/journal.pone.0005018.g003
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PLoS ONE | www.plosone.org 6 March 2009 | Volume 4 | Issue 3 | e5018Figure 4. Cidofovir alters CXCR4 gene and cell surface receptor expression. (A) Quantitative RT-PCR analysis of CXCR4 mRNA level in HeLa
cells treated or not with SDF-1 and CXCR4- specific probe. **P,0.05. (B, C) FACS analysis of the cell surface expression of the receptor CXCR4 on HeLa
(10
5 cells/mL) (B) and (C) TC-1 cells (10
5 cells/mL) treated or not with Cidofovir. Purple area=isotype control. (D) Subcellular localization of the CXCR4
receptor in HeLa studied by confocal microscopy using de MAB173 antibody from R&D System) at 1 mg/mL.
doi:10.1371/journal.pone.0005018.g004
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PLoS ONE | www.plosone.org 7 March 2009 | Volume 4 | Issue 3 | e5018Figure 5. Cidofovir abrogates TC-1 cell lung metastasis in vivo in a CXCR4 dependent manner. In the two first groups, TC-1 cells were
either untreated or pre-treated for 6 days with 10 mM Cidofovir prior to vein tail injection. In the third group, mice were systemically treated with
Cidofovir (100 mg/Kg) 2 h before TC-1 cell injection and then on day at day 2, 4, 6, 8. Lungs were collected and processessed for histology. (A)
Representative Hematoxylin-Eosin-Saffranin (HES)-stained sections of lungs of mice are shown. Metastases are delineated by a dashed line.
b=bronchi, v=vessel (B) Quantitative assessment of lung macro-metastasis was performed as previously described ***P,0.01 as compared to
untreated group. (C) CXCR4 immunostaining was performed as previously described.
doi:10.1371/journal.pone.0005018.g005
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and E7 expression could also strengthen tumor cell capability to
home into distant metastatic sites in conjunction with microenvi-
ronmental stimuli, including the SDF-1a/CXCR4 axis. We
developed in vitro and in vivo functional assays modeling the
extravasation step of the metastatic process along with immuno-
logical, genetic and pharmacological approaches targeting
CXCR4 or E6/E7 oncoproteins and showed a contribution of
the SDF-1a/CXCR4/Rho/ROCK cascade and E6/E7 onco-
proteins in experimental metastasis. In addition, our results
suggested a new therapeutic strategy whereby HPV
+ tumor cell
homing and invasion may be prevented by an approved systemic
agent, Cidofovir.
In the classical model of metastasis [35], a small subpopulation
of permissive cells within a specific tumor microenvironment
acquire genetic and epigenetic alterations that enable them to
metastasize to distant sites after intravasation, transit in the blood
or lymph, extravasation and growth. Extravasation typically
occurs after attachment of circulating tumour cells to the vessel
wall, directed by tissue-specific extracellular chemokines. The
SDF-1a/CXCR4 axis belongs to this class of mediators and recent
studies have shown that inhibition of CXCR4 with antibodies,
peptide antagonists or siRNA all reduce metastasis in several solid
tumors, including breast [8,36,37,38], melanoma [12,39], pancre-
as [40], prostate [41] and colon [42] cancers. Contribution of the
SDF-1a/CXCR4 axis to the migration of cervix carcinoma cells
was suspected; indeed a pro-migratory action of the SDF-1a has
been reported in HeLa cells [43,44]. In addition, transcriptional
activation of the CXCR4 promoter is described in cervix
carcinoma [45] and immunohistochemistry has shown high
CXCR4 expression on cervix cancer cells [11]. Further implica-
tion of CXCR4 receptors in the metastatic process was extended in
vivo. Inhibition studies with a CXCR-4-blocking-antibody almost
completely abrogated pulmonary colonization in vivo. The current
study showed that SDF-1a stimulated the invasive phenotype of
human and rodent tumor cells. SDF-1a incubation stimulated the
CXCR4 cascade without altering CXCR4 gene transcription, but
activated one downstream signaling, i.e. the Rho/ROCK
pathway. Findings are consistent with Bartolome et al’s previous
report, which showed that RhoA activity was enhanced in murine
B16F10 melanoma cells upon SDF-1 stimulation [12] and
involved the two Rho-GTPase guanine-nucleotide exchange
factors Vav1 and Vav2 [13]. In addition, direct monitoring of
ROCK activity (i.e. phosphorylation of the MLC) in vitro, and its
pharmacological inhibition (i.e. Y-27632) in vivo, showed a
contribution of ROCK activity to SDF-1 stimulation and lung
homing of tumor cells expressing E6/E7. This last finding is not
consistent with Charette et al’s report, which showed that
inhibition of ROCK enhanced migration of normal keratinocytes
transfected with E7. These discrepancies are probably due to the
different methodologies used. Charette et al. used normal
keratinocytes and an in vitro 2-D migration assay, which are more
representative of initial steps of the metastatic process. In contrast,
our data is mainly from in vivo experiments. Such an approach is
more relevant to the pathophysiological process and relates to later
steps of the metastatic process including organ homing and
invasion. However, the fact that ROCK blockade was less efficient
at metastasis inhibition than direct CXCR4 blockade, suggests
involvement of other pathways downstream of CXCR4, such as
the PI3 kinase/Akt pathway [44].
A significant question addressed in this work is the contribution
of the E6 and E7 oncogenes in determining the extent of the
invasive phenotype. Integration of papilliomaviruses into the host
genome of cancer cells has been suggested to be one of the initial
genetic events leading to metastasis [27,34] and transfection of the
oncoprotein E7 has been shown to trigger the early steps of the
metastatic conversion in human keratinocytes via stimulation of the
Figure 6. Cidofovir inhibits Rho/p160ROCK activation induced
by SDF-1/CXCR4. (A) Active Rho was isolated by pull-down assay
from HeLa and TC-1 cells after treatment with 100 ng/mL SDF-1 and
10 mM Cidofovir. Densitometric quantification was performed using
ImageJ software. **P,0.05, ***P,0.01. (B) Membrane-associated Rho
was studied by confocal microscopy. (C) p160ROCK activity was
indirectly assessed by measuring myosin light chain phosphorylation
(MLC-p). Densitometric analyses were performed using ImageJ soft-
ware. ***P,0.01.
doi:10.1371/journal.pone.0005018.g006
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of the PI3K/Akt pathway [27]. In the present study, relationship
between E6/E7 expression and the SDF-1a/CXCR4 axis was
postulated. We showed that E6/E7 gene silencing or pharmaco-
logical inhibition using Cidofovir exhibited similar effects,
disrupting the SDF-1-induced invasion process, decreasing
CXCR4 expression and inhibiting both constitutive and SDF-1-
induced Rho/ROCK activation. These results suggested that E6/
Figure 7. p160ROCK inhibition reduces HeLa migration in vitro and TC-1 cell lung metastasis in vivo. Matrigel assay were performed as
previously described with HeLa cells pre-treated for 30 min 10 mM Y-27632. *P,0.05. (B) TC-1 cells were harvested and injected as previously
described. Before injection to the mice, TC-1 cells were un-treated or pre-treated for 30 min. with 10 mM Y-27632. Lungs were collected, paraffin-
embedded, fixed and cuted into sections. (A) Sections were stained with Hematoxylin-Eosin-Saffranin (HES) and (B) Quantitative assessment of lung
macro-metastasis was performed as previously described. ***P,0.01 as compared to untreated group.
doi:10.1371/journal.pone.0005018.g007
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for its abrogation in cervix cancer patients by using an anti-viral
agent, Cidofovir, as a therapeutic tool. Potential non-specific
toxicity of Cidofovir was carefully investigated in vitro and in vivo
and at the concentration used, Cidofovir toxicity was found to be
minimal, suggesting that its anti-metastatic action was not
mediated through a simple killing process. While Cidofovir
displays several intracellular actions such as cytostatic, radiosen-
sitizing and anti-angiogenic actions, our group and others showed
that Cidofovir and some of its derivates act preferentially on E6
and E7-expressing cells [29,46,47,48,49] inducing an S-phase
block [50,51] associated with decreased levels of E6 and E7,
increased p53 and pRb levels. Consistently, the present study
showed no anti-migratory effect of Cidofovir on HPV-negative
B16F10 cells, but we report that the pro-invasive signals triggered
by SDF-1a were occuring in HPV negative cells (i.e. B16F10),
suggesting that SDF-1a/CXCR4 activation is not specific to E6/
E7 expressing cells.
In summary, the present results show contribution of the SDF-
1a/CXCR4/Rho/ROCK cascade in the metastatic process
which is enhanced by the expression of E6 and E7 oncoprotein.
These results show that E6/E7 act as enhancers of the metastatic
process rather than initiators. Besides expression of E6 and E7
genes, additional events such as Ras activation could increase
malignant conversion and tumor forming ability of HPV
expressing cells [52,53] and will worth careful investigation in
the future. Finally, we showed for the first time an effective
therapeutic inhibition of metastasis in E6/E7 expressing cells using
Cidofovir in a dose-range suitable for clinical use. These data
provided a compelling rational for investigation of a phase I
clinical trial conducted at our Institution to assess Cidofovir
toxicity in cervix patients (PHRC 2006).
Materials and Methods
Cell lines and treatments
HeLa human cervix carcinoma (HPV18
+) were cultured in
DMEM supplemented with 10% FCS, 50 U/ml penicillin/
streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate and
2 mM non-essential amino acids (CCL-2, Promochem, France).
Mouse lung carcinoma TC-1 cells (HPV16
+) were cultured in
RPMI 1640 supplemented with 10% FCS, 50 U/ml penicillin/
streptomycin, 2 mM L-glutamine addition of 1 mM sodium
pyruvate, 2 mM non-essential amino acids and 0.4 mg/ml G418
(CRL-2785, Promochem, France). TC-1 cells were initially
obtained by co-transformation of primary C57BL/6 mouse lung
epithelial cells with HPV-16 E6 and E7 and activation of Ras
oncogene [33] and used in the present study to generate lung
metastasis in mice as previously described [33]. The TC-1
metastasis model was used because HeLa cells do not form
spontaneous metastases when injected into nude mice. Mouse
melanoma B16F10 cells are HPV-negative and were used to
monitor the specificity of Cidofovir action. They were cultured in
DMEM supplemented with 10% FCS, 50 U/ml penicillin/
streptomycin, 2 mM L-glutamine.
Cells were collected by gentle scraping to maintain the CXCR4
receptor at the cell surface. CXCR4 blocking antibodies were,
respectively, 12G5 for HeLa cells (10 mg/mL; R&D system) and
2B11 for TC-1 and B16F10 cells (10 mg/mL; R&D system).
Positive and negative control experiments were performed by pre-
incubating scraped cells with an irrelevant antibody (monoclonal,
CD71, 10 mg/mL, BD Pharmingen) or trypsin/EDTA (Gibco).
To shut-down E6/E7 expression, HeLa, TC-1 cells and B16F10
were treated in vitro with 10 mM Cidofovir (Pharmacia Upjohn,
Guyancourt les Yvelines, France) for 6 days. Concentration and
timing have been optimized in previous experiments [29,47] and
efficiently switched-off E6/E7 expression. Similarly, scraped cells
were treated with Y-27632 10 mM (Tocris) for 30 min before
seeding or IV injection. In addition, E6/E7 expression was stably
knocked-down in HeLa cells using the pEBVsiRNA as previously
described [30]. Silenced HeLa cells were termed as HeLa KD
(knock down) cells. For each gene, 3 vectors were constructe, selected
with hygromycin and sub-cultured in presence of hygromycin
(125 mg/mL, Invitrogen). Each siRNA sequence and its position
are indicated Table 1. Inhibition of E6 and E7 was checked by Q-
RT-PCR as previously described [47], E6 primers were as follows:
Fwd 59- gcg acc cta caa gct acc tg -39 and Rev 59- aga cag tat acc cca tgc tg
-39 and E7 primers were as follows: Fwd 59- aga aac cca gct gta atc -39
and Rev 59- tta tgg ttt ct gaga aca ga -39 (Perkin-Elmer Corp./PE
Applied Biosystems).
Western-blot analysis
Western-blot analysis was conducted as already described [47].
Briefly total protein was isolated, subjected to SDS polyacrylamide
gel electrophoresis and electrotransfered onto nitrocellulose
membranes. Monoclonal antibodies against E6 (1:2500, clone
C1P5, Abcam) was used as well as anti-b-actin antibody (clone
AC-15, Sigma) to control protein loading.
Cytotoxicity
Cell survival after Cidofovir treatment was monitored using
trypan blue exclusion and MTT assays. Apoptosis was monitored
by TUNEL assay (Roche) according to manufacturer instructions
and subsequent confocal observation. Clonogenic survival assay
were also performed in vitro using increasing concentration of
Cidofovir (1–10 mM) and in vivo monitoring tumor growth.
Cidofovir anti-clonogenic action was monitored by sub-cutaneous
injection of TC-1 and follow-up of tumor engraftment and growth.
Mice were divided into 3 groups (n=6mice/group): 4 million of
untreated TC-1, 4 million of Cidofovir-pretreated TC-1 and 8
million of Cidofovir-pretreated TC-1.Toxicity of Cidofovir was
assessed to make comparison between control and Cidofovir-
treated cells possible. The number of cells used in the various
experiments was corrected according to these results to be sure
that the exact same number of living cells was seed in control and
Cidofovir-treated cells.
Tumor cell invasion assay
As an in vitro model system for metastasis, we performed
matrigel invasion assay using transwell chambers (24-well format,
8-mm pore size; thin matrigel layer; BD Falcon). Human
Table 1. pEBVsiRNA sequences.
pEBVsiRNA plasmid Position (nt)
Sequence
pEBVsiHPV18E6-104R 104–122
59-GCAAGACAGTATTGGAACT-39
pEBVsiHPV18E7-609R 609–627
59-CAAGACATTGTATTGCATT-39
pEBVsiHPV18E7-698R 698–716
59-CGATGAAATAGATGGAGTT-39
pEBVcontrol [30]
doi:10.1371/journal.pone.0005018.t001
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FCS free medium was added to the bottom chamber to induce
cells’ invasion through the matrigel. Cells were pre-treated using:
1) CXCR4-blocking antibody (10 mg/mL) and 2) Cidofovir and 3)
Y-27632. The antibody concentration was based on Li et al’s
previous report [8]. For each treatment group 5610
5 cells were
seeded into the top chamber. Matrigel invasion chambers were
incubated for 24 hours at 37uC and non-invading cells removed
from the top of the matrigel using a cotton-wool swab. Invading
cells at the bottom of the chamber were fixed and stained with
crystal violet. The invasion rate was determined by counting the
crystal violet-stained cells. Results were expressed as the mean
number of invaded cells2/+SD. Similar procedure was used for
E6
KD and E7
KD HeLa cell lines. Three independent experiments
were performed, with three chambers in each treatment group.
Metastasis experiment in vivo, histology and
immunohistochemistry
Experiments were performed with 10-week-old female C57BL/
6 mice (Harlan, France). Experiments were conducted under the
French regulations for animal experimentation (Ministry of
Agriculture ActNo.87-848, 19
th of October, 1987) and received
ethics approval.TC-1 cells were harvested by gentle scraping in
FCS free RPMI 1640 to obtain single-cell suspension. Cells were
pre-incubated 30 min with CXCR4-blocking antibody, irrelevant
antibody (CD71) and trypsin/EDTA respectively. To shut-down
E6/E7 expression, TC-1 cells were pre-incubated for 6 days with
Cidofovir as previously described. One million TC-1 cells in
0.1 ml FCS-free medium were injected into mouse tail veins using
a 25-gauge needle. Mice were divided into 6 groups according to
the pre-treatment cells received (n=5–9 mice/group): carrier
only, CXCR4-blocking antibody, irrelevant antibody (CD71),
trypsin/EDTA, Cidofovir and Y-27632. The anti-metastatic
efficacy of Cidofovir was also assessed after systemic administra-
tion of Cidofovir at 100 mg/kg, a non-toxic dose used in
previously experiments [29]. 8 mice received intra-peritonal
injection of Cidofovir 2 h prior IV injection of 1 million TC-1
cells and subsequent injection at day 2, 4, 6, 8. At the end of 15
days follow up and whatever treatments they had all mice were
killed [33]. Lungs and spleen were collected for histology and
immunohistochemistry. Spleen was collected to monitor possible
immune-related activation. Organs were fixed in Finefix (Mile-
stone medical, Italy), paraffin embedded and cut into 4 mm
sections. Sections were stained with Hematoxilin-Eosin-Saffranin
(HES) and examined using conventional light microscopy.
Assessment of lung macro-metastasis was performed on HES-
stained section digitized with a slide scanner (Super-coolscan 8000
ED; Nikon) and analyzed with the ImageJ software downloaded
from http://rsb.info.nih.gov/ij/ to determine the total metastatic
surface per lung of each mouse. CXCR4 immunostaining was
performed using a goat polyclonal antibody raised against
CXCR4 and incubated overnight at 4uC( n u201-819; 1:300;
Alexis Biochemicals). Primary antibody incubation was followed
by incubation with rabbit anti-goat serum for 30 min. (1:50,
Dako), streptavidin-HRP for 30 min. (1:100, Dako) and revealed
with DAB substrate (Dako).
FACs analysis
FACs analysis of CXCR4 surface expression was studied using a
specific CXCR4 receptor monoclonal antibody 12G5-PE for
HeLa cells (10 mg/mL; BD Pharmingen, Le Pont-De-Claix –
France) and 2B11-PE for TC-1 (10 mg/mL; R&D system). Cells
were stained with appropriate dilutions of the antibodies or
isotype-matched controls. After one wash, cells were suspended in
phosphate-buffered saline (PBS), kept at 4uC, and analyzed on a
FACsort (Becton, Dickinson) with the CellQuest Pro-software
package.
Confocal microscopy analysis
Immunofluorescence was evaluated by laser scanning confocal
microscopy (Zeiss LSM510, Carl Zeiss SAS, France) after fixation
of sub-confluent HeLa cells with paraformaldehyde 1% and
incubation with appropriate primary and secondary antibodies.
Labeling was performed with a primary mouse anti-CXCR4
monoclonal antibody (MAB173; 1:250, R&D Systems, Abingdon
– UK) and a secondary goat F(ab9)2 anti-mouse IgG2b FITC -
coupled antibody (1:500; Santa Cruz, Tebu bio, France), anti-Rho
A/B/C (H-70) rabbit IgG polyclonal antibody (1:300; Santa Cruz,
Tebu-bio, France) with secondary antibody Alexa Fluor-546
conjugated goat anti-rabbit IgG (1:300) (Molecular Probes,
Eugene, OR).
Real-time PCR
Total RNA was isolated from cells using an RNeasy mini kit
according to the manufacturer’s instructions (QIAGEN, Hilden,
Germany). The quality of RNA was assessed using a bioanalyser
(Agilent, Les Ulis, France) and 1 microgram of total RNA was
reverse transcribed as described [47]. CXCR4 primers were as
follows: TaqMan 59- cag cag gta gca aag tga cgc cga -39, Fwd 59- gtt tgt
tgg ctg cgg -39 and Rev 59- gtc ata gtc ccc tga gcc ca -39 (Perkin-Elmer
Corp./PE Applied Biosystems). Real-time quantitative PCR was
achieved according to the manufacturer’s instructions and
normalized to 18S ribosomal RNA (Perkin-Elmer Corp./PE
Applied Biosystems).
Rho and ROCK activity assay
For the Rho pull down assay, cells were incubated with 100 ng/
mL of recombinant human SDF-1a ligand (R&D Systems) 15 min
before protein collection. The Rho-GTP form was isolated by pull-
down assay (Pierce, Perbio, France) according to the manufactur-
er’s instructions. Anti-Rho A/B/C (H-70) rabbit IgG polyclonal
antibody from Santa-Cruz (1:1000) was used to detect total Rho
protein, whereas anti-Rho mouse monoclonal antibody from
Pierce was used for Rho-GTP detection (1:500, Pierce, Perbio –
France).
ROCK activity was indirectly assessed by monitoring the
phosphorylation status of the MLC (Myosin light chain). Cells
were gently scraped from flasks in cold PBS, with a protease
cocktail inhibitor (Roche Diagnostics, GmbH, Germany) and anti-
phosphatase (orthovanadate 5 mM), then lysis buffer (10 mM
HEPES pH=8, 0.1 mM EGTA pH=8, 0.01 M KCl, 1 mM
DTT, 0.62% NP40, protease inhibitor and orthovanadate 5 mM)
was added. Protein concentrations were assessed by Bradford assay
(Bio-Rad, Marnes-la-Coquette, France) and Western blots were
performed as described [47]. Anti-MLC II rabbit polyclonal was
from Santa Cruz (1:500; Tebu-bio, France) and anti-MLC-
phospho (Ser19) rabbit polyclonal from Stressgen (1:400; France).
Anti-GAPDH mouse polyclonal (1:5000, Biodesign, France) was
used as loading control.
Statistical analyses
All values are reported as mean (SEM). Data were analysed
using one way ANOVA and the Student-Newman-Keuls test.
Supporting Information
Figure S1
Found at: doi:10.1371/journal.pone.0005018.s001 (0.43 MB TIF)
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